Exosome-loaded degradable polymeric microcapsules for the treatment of vitreoretinal diseases

Bao, Han; Tian, Ying; Wang, Haixin; Ye, Tong; Wang, Shuang; Zhao, Jiawei; Qiu, Yefeng; Li, Jian; Pan, Chao; Ma, Guanghui; Wei, Wei; Tao, Yong

doi:10.1038/s41551-023-01112-3

Cited by 13 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, enhancing vitreous retention and targeting ability may be the key point for improving the therapeutic efficiency of EVs in DR. In a current paper by Bao et.al 127 , BMSC-EVs were encapsulated within polymeric microcapsules, allowing for controlled release as the capsules gradually degrade. These microencapsulated EVs not only show enhanced biological stability but also demonstrate sustained release for more than one month following intravitreal injection in a mouse model of retinal ischemia-reperfusion injury.…”

Section: Ev-based Therapy In Drmentioning

confidence: 99%

Emerging role of extracellular vesicles in diabetic retinopathy

Zhu,

Huang,

Sun

et al. 2024

Theranostics

View full text Add to dashboard Cite

Diabetic retinopathy (DR), a complex complication of diabetes mellitus (DM), is a leading cause of adult blindness. Hyperglycemia triggers DR, resulting in microvascular damage, glial apoptosis, and neuronal degeneration. Inflammation and oxidative stress play crucial roles during this process. Current clinical treatments for DR primarily target the advanced retinal disorder but offer limited benefits with inevitable side effects. Extracellular vesicles (EVs) exhibit unique morphological features, contents, and biological properties and can be found in cell culture supernatants, various body fluids, and tissues. In DR, EVs with specific cargo composition would induce the reaction of receptor cell once internalized, mediating cellular communication and disease progression. Increasing evidence indicates that monitoring changes in EV quantity and content in DR can aid in disease diagnosis and prognosis. Furthermore, extensive research is investigating the potential of these nanoparticles as effective therapeutic agents in preclinical models of DR. This review explores the current understanding of the pathological effects of EVs in DR development, discusses their potential as biomarkers and therapeutic strategies, and paves the way for further research and therapeutic advancements.

show abstract

Section: Ev-based Therapy In Drmentioning

confidence: 99%

Emerging role of extracellular vesicles in diabetic retinopathy

Zhu,

Huang,

Sun

et al. 2024

Theranostics

View full text Add to dashboard Cite

show abstract

“…Another significant advantage of polymeric materials as drug carriers is their capacity to sustain drug activity while providing continuous release to the retina. , For instance, injectable hydrogel-delivered cells have demonstrated the promotion of cell survival, differentiation, integration, and repair. , Wang et al devised a local immunotherapy strategy to control retinoblastoma and preserve vision, employing an injectable hydrogel encapsulating GD2-specific CAR-T cells for localized and sustained cell delivery . Another polymeric materials, PLGA, has exhibited continuous release of therapeutic exosomes for a duration of up to 35 days …”

Section: Conventional Nanocarriers For Retinal Diseasementioning

confidence: 99%

Smart Nanocarriers for the Treatment of Retinal Diseases

Liu,

Yan,

Huang

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Retinal diseases, such as age-related macular degeneration, diabetic retinopathy, and retinoblastoma, stand as the leading causes of irreversible vision impairment and blindness worldwide. Effectively administering drugs for retinal diseases poses a formidable challenge due to the presence of complex ocular barriers and elimination mechanisms. Over time, various approaches have been developed to fabricate drug delivery systems for improving retinal therapy including virus vectors, lipid nanoparticles, and polymers. However, conventional nanocarriers encounter issues related to the controllability, efficiency, and safety in the retina. Therefore, the development of smart nanocarriers for effective or more invasive long-term treatment remains a desirable goal. Recently, approaches have surfaced for the intelligent design of nanocarriers, leveraging specific responses to external or internal triggers and enabling multiple functions for retinal therapy such as topical administration, prolonged drug release, and site-specific drug delivery. This Review provides an overview of prevalent retinal pathologies and related pharmacotherapies to enhance the understanding of retinal diseases. It also surveys recent developments and strategies employed in the intelligent design of nanocarriers for retinal disease. Finally, the challenges of smart nanocarriers in potential clinical retinal therapeutic applications are discussed to inspire the next generation of smart nanocarriers.

show abstract

“…[85] Studies have disclosed that PLGA nanoparticles loaded with fenofibrate and pioglitazone, respectively, are also efficient treatments for AMD and DR. [86] Intriguingly, Bao et al reported exosome-loaded degradable PLGA nanoparticles with micrometric pores, where PLGA helped induce a mild self-healing process during which the superficial surface pores healed, creating specific "ExoCap" pseudo cells and then contributed to sustainedly releasing therapeutic exosomes as the nanoparticles degraded, to treat vitreoretinal diseases. [87] Moreover, further modified PLGA nanoparticles could fulfill the co-delivery of multiple drugs targeting different pathogenic factors, which has been recognized as a promising strategy, offering advantages over monotherapy in tackling multifactorial diseases. To this end, electrostatically conjugated bevacizumab-bearing PLGA/PEI nanoparticles loaded with dexamethasone (aBev-DPPNs) were developed, where the inclusion of PEI, extensively employed in DDSs because of its proton sponge effect, [88] facilitated the absorption of bevacizumab.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management

Zhou,

Xu,

Shen

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

As an indispensable part of the human sensory system, visual acuity may be impaired and even develop into irreversible blindness due to various ocular pathologies. Among ocular diseases, fundus neovascularization diseases (FNDs) are prominent etiologies of visual impairment worldwide. Intravitreal injection of anti‐vascular endothelial growth factor drugs remains the primary therapy but is hurdled by common complications and incomplete potency. To renovate the current therapeutic modalities, nanomedicine emerged as the times required, which has been endowed with advanced capabilities, able to fulfill the effective ocular fundus drug delivery and achieve precise drug release control, thus further improving the therapeutic effect. This review provides a comprehensive summary of advances in nanomedicine for FND management from state‐of‐the‐art studies. Firstly, we thoroughly introduce the current therapeutic modalities for FNDs, focusing on the key challenges of ocular fundus drug delivery. Secondly, we comprehensively reviewed nanocarriers for ocular posterior drug delivery based on the nanostructures: polymer‐based nanocarriers, lipid‐based nanocarriers, and inorganic nanoparticles. Thirdly, we elaborate on the characteristics of the fundus microenvironment, their pathological changes during FNDs, and corresponding strategies for constructing smart nanocarriers. Furthermore, the challenges and prospects of nanomedicine for FND management are thoroughly discussed.This article is protected by copyright. All rights reserved

show abstract

Exosome-loaded degradable polymeric microcapsules for the treatment of vitreoretinal diseases

Cited by 13 publications

References 52 publications

Emerging role of extracellular vesicles in diabetic retinopathy

Emerging role of extracellular vesicles in diabetic retinopathy

Smart Nanocarriers for the Treatment of Retinal Diseases

Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management

Contact Info

Product

Resources

About